Elo Mutual Pension Insurance Co Acquires 2,777 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Elo Mutual Pension Insurance Co grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,860 shares of the medical research company’s stock after purchasing an additional 2,777 shares during the period. Elo Mutual Pension Insurance Co’s holdings in IQVIA were worth $3,706,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after buying an additional 59,426 shares in the last quarter. Cantillon Capital Management LLC increased its stake in shares of IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after buying an additional 226,017 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQVIA stock opened at $177.27 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $31.25 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business has a 50-day moving average of $193.15 and a 200 day moving average of $206.47. IQVIA Holdings Inc. has a 12 month low of $176.03 and a 12 month high of $253.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on IQV shares. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.